In the field of oncology treatment, the introduction of each innovative drug is like lighting a beacon of hope for patients. Recently, Beijing GoBroad Hospital has once again positioned itself at the forefront of cancer treatment by successfully introducing Aiparoli-Tovoraly Monoclonal Antibody Injection, developed using the globally pioneering MabPair™ dual-antibody platform. As the first hospital in Beijing to provide this groundbreaking medication, GoBroad Hospital offers a new treatment option for patients with recurrent or metastatic cervical cancer who have failed prior platinum-based chemotherapy. This introduction not only highlights the hospital’s expertise in oncology treatment but also brings new hope and possibilities to many cervical cancer patients.

Rapid Introduction of New Drugs to Benefit Cervical Cancer Patients

On October 25, 2024, Aiparoli-Tovoraly Monoclonal Antibody Injection was officially made available at Beijing GoBroad Hospital’s pharmacy, marking a significant step in providing the latest treatment solutions for cervical cancer patients.

One of the first beneficiaries is Ms. Wang, a 32-year-old woman diagnosed with stage IV cervical cancer with multiple lymph node, bone, and lung metastases. Her battle against cancer has been extremely challenging. Since March 2022, she has undergone surgery followed by postoperative radiotherapy and chemotherapy. However, in June 2023, new lung metastases, along with cervical, supraclavicular, and mediastinal lymph node metastases, were detected. From July 2023 onward, she underwent systemic chemotherapy, anti-angiogenic therapy, immune checkpoint inhibitor treatment, and localized vascular interventional chemotherapy. Unfortunately, her condition continued to progress. Given her high tumor burden, urgently controlling disease progression became a critical priority.

 

Dr. Wang Shasha Assesses the Patient’s Condition

 

 On October 27, 2024, Dr. Wang Shasha, the attending physician of the New Drug Clinical Team at the Oncology Immunotherapy Department of Beijing GoBroad Hospital, issued the first prescription for Aiparoli-Tovoraly Monoclonal Antibody Injection. This marks yet another milestone for the team in prescribing a newly introduced drug in Beijing, demonstrating GoBroad’s efficiency in rapidly bringing innovative treatments to patients.

On the same day, Ms. Wang received a treatment regimen of Aiparoli-Tovoraly 200mg combined with liposomal doxorubicin, which was successfully administered with no significant discomfort. This treatment plan has brought new hope to both Ms. Wang and the medical team caring for her. It is anticipated that Aiparoli-Tovoraly will provide therapeutic benefits, help control tumor progression, and offer a new turning point in her fight against cancer.

 Beijing GoBroad Hospital Issues Its First Prescription for Aiparoli-Tovoraly Monoclonal Antibody Injection

 

 First Standard Treatment Drug Preparation for Aiparoli-Tovoraly Monoclonal Antibody Injection

 

Beijing GoBroad Hospital’s First Patient to Receive Aiparoli-Tovoraly Monoclonal Antibody Injection

 

Aiparoli-Tovoraly Monoclonal Antibody: Dual Mechanism for Enhanced Efficacy and Reduced Toxicity

Aiparoli-Tovoraly Monoclonal Antibody is a globally first-in-class bispecific antibody developed using Qilu Pharmaceutical’s MabPair® technology platform. It features an optimized 2:1 ratio of PD-1 and CTLA-4 antibodies, enhancing drug stability and safety. This unique design leverages a dual immune mechanism, effectively lifting T-cell activation suppression while targeting and eliminating Treg cells that inhibit anti-tumor immune responses. By improving the tumor microenvironment, it achieves the goal of enhanced efficacy with reduced toxicity, offering a new treatment option for patients with recurrent or metastatic cervical cancer.

 On September 30, 2024, Aiparoli-Tovoraly Monoclonal Antibody Injection was approved for market release

 

GoBroad’s Strength, Building Hope for Patients

As a pioneer in the research-driven hospital model in China, GoBroad Hospital has consistently leveraged its strengths in innovation, research transformation, and clinical application. The rapid introduction of Aiparoli-Tovoraly Monoclonal Antibody Injection is a testament to GoBroad Hospital’s efficient process for integrating innovative therapies into clinical practice.

Looking ahead, GoBroad Hospital remains committed to its patient-centered mission, continuously accelerating the adoption of innovative drugs, enhancing clinical applications, and strengthening patient support. By ensuring that groundbreaking treatments truly benefit patients, the hospital contributes to the advancement of China's pharmaceutical industry, helping more individuals improve their quality of life and return to normalcy.